Overview

Pimavanserin for Sleep in Parkinson Disease

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g., visual hallucinations, delusions) and sleep problems.
Phase:
Early Phase 1
Details
Lead Sponsor:
State University of New York - Downstate Medical Center
Collaborator:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin